Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.

Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR.

Aliment Pharmacol Ther. 2018 Mar;47(6):763-772. doi: 10.1111/apt.14510. Epub 2018 Jan 22.

2.

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR.

Inflamm Bowel Dis. 2018 May 18;24(6):1185-1192. doi: 10.1093/ibd/izy031.

3.

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).

Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.

Scand J Gastroenterol. 2018 Feb;53(2):158-167. doi: 10.1080/00365521.2017.1416160. Epub 2017 Dec 19.

PMID:
29258369
4.

Vedolizumab for induction and maintenance of remission in ulcerative colitis.

Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, MacDonald JK, Khanna R, Feagan BG.

Cochrane Database Syst Rev. 2014 Aug 8;(8):CD007571. doi: 10.1002/14651858.CD007571.pub2. Review.

PMID:
25105240
5.

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.

J Crohns Colitis. 2017 Aug 1;11(8):921-929. doi: 10.1093/ecco-jcc/jjx021. Erratum in: J Crohns Colitis. 2018 Mar 28;12(4):510.

PMID:
28333288
6.

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.

Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K.

J Crohns Colitis. 2019 Feb 1;13(2):172-181. doi: 10.1093/ecco-jcc/jjy149.

7.

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.

Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M.

Clin Gastroenterol Hepatol. 2017 Feb;15(2):229-239.e5. doi: 10.1016/j.cgh.2016.08.044. Epub 2016 Sep 14.

8.

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.

Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J.

BMC Gastroenterol. 2018 Sep 15;18(1):140. doi: 10.1186/s12876-018-0868-x.

9.

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.

Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860. doi: 10.1093/ibd/izx067.

10.

One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.

Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y; OBSERV-IBD study group and the GETAID.

Aliment Pharmacol Ther. 2017 Aug;46(3):310-321. doi: 10.1111/apt.14167. Epub 2017 Jun 8.

11.

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212. doi: 10.1111/apt.13813. Epub 2016 Oct 7.

12.

Long-term Efficacy of Vedolizumab for Ulcerative Colitis.

Loftus EV Jr, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M.

J Crohns Colitis. 2017 Apr 1;11(4):400-411. doi: 10.1093/ecco-jcc/jjw177.

PMID:
27683800
13.

Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.

Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, Khanna R, Feagan BG.

Inflamm Bowel Dis. 2015 May;21(5):1151-9. doi: 10.1097/MIB.0000000000000396. Review.

PMID:
25844963
14.

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.

Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, Korzenik J.

Dig Dis Sci. 2017 Jun;62(6):1590-1596. doi: 10.1007/s10620-017-4549-3. Epub 2017 Mar 29.

15.

Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.

Smith MA, Mohammad RA.

Ann Pharmacother. 2014 Dec;48(12):1629-35. doi: 10.1177/1060028014549799. Epub 2014 Sep 3. Review.

PMID:
25186623
16.

Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.

Jin Y, Lin Y, Lin LJ, Zheng CQ.

World J Gastroenterol. 2015 May 28;21(20):6352-60. doi: 10.3748/wjg.v21.i20.6352. Review.

17.

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D; European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives.

Gastroenterology. 2016 Feb;150(2):380-8.e4. doi: 10.1053/j.gastro.2015.10.050. Epub 2015 Nov 26.

18.

The impact of biological interventions for ulcerative colitis on health-related quality of life.

LeBlanc K, Mosli MH, Parker CE, MacDonald JK.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD008655. doi: 10.1002/14651858.CD008655.pub3. Review.

PMID:
26393522
19.

Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.

Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D.

J Crohns Colitis. 2017 Oct 1;11(10):1230-1237. doi: 10.1093/ecco-jcc/jjx082. Erratum in: J Crohns Colitis. 2018 Apr 27;12(5):630.

PMID:
28605483
20.

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr.

J Gastroenterol. 2018 Sep;53(9):1048-1064. doi: 10.1007/s00535-018-1480-0. Epub 2018 Jun 4.

Supplemental Content

Support Center